Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Arzerra First Quarter 2012 Net Sales Figures25 Apr 2012
Passing of Genmab A/S’ Annual General Meeting25 Apr 2012
Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to Employees25 Apr 2012
Report Pursuant to Section 28a of the Danish Securities Trading Act25 Apr 2012
Genmab Revised Financial Calendar for 201218 Apr 2012
Genmab A/S Summons Annual General Meeting27 Mar 2012
Genmab Announces Patent Settlement Agreement for Ofatumumab26 Mar 2012
Major Shareholder Announcement
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
23 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL19 Mar 2012
Genmab 2011 Annual Report7 Mar 2012
Genmab Reaches Second Milestone in Lundbeck Collaboration10 Feb 2012
Arzerra Fourth Quarter and Full Year 2011 Net Sales Figures7 Feb 2012
  • Previous
  • 1
  • More pages
  • 93
  • 94
  • 95
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863